Modulation and Intensification of a Cyclophosphamide, Hexamethylmelamine, Doxorubicin, and Cisplatin Ovarian Cancer Regimen
For 61 patients with stage III-IV carcinoma of the ovary, chemotherapy consisted first of cisplatin 50 mg/m on day 1, cyclophosphamide 500 mg/m on day 3, doxorubicin 50 mg/m on day 3, and hexamethylmelamine 100 mg/m on days 4-15 every 4 weeks. The dosages of doxorubicin and hexamethylmelamine were i...
Gespeichert in:
| Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 1989-03, Vol.73 (3), p.349-356 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 356 |
|---|---|
| container_issue | 3 |
| container_start_page | 349 |
| container_title | Obstetrics and gynecology (New York. 1953) |
| container_volume | 73 |
| creator | BRUCKNER, HOWARD W COHEN, CARMEL J FEUER, ERIC HOLLAND, JAMES F |
| description | For 61 patients with stage III-IV carcinoma of the ovary, chemotherapy consisted first of cisplatin 50 mg/m on day 1, cyclophosphamide 500 mg/m on day 3, doxorubicin 50 mg/m on day 3, and hexamethylmelamine 100 mg/m on days 4-15 every 4 weeks. The dosages of doxorubicin and hexamethylmelamine were increased by 60 and 100%, respectively, until the nadir white blood cell counts fell to 1.0 x 10/L. This regimen was less neurotoxic and nephrotoxic than other intensive treatments and produced better therapeutic effects than did the immediate preceding Mount Sinai regimens1) The overall median survival was 43 months and progression-free survival was 25 months; 2) the greatest benefit occurred among patients under 50 years of age; 3) regression of large tumors increased in frequency, with 33% of tumors 2-6 cm and 16% of tumors larger than 6 cm converted to either pathologically proved remission or microscopic |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_2492648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2492648</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2801-eb1596013729c522fe97ec0ca592de3db25deaa3bcfc3036a305ec4a54fb4cb93</originalsourceid><addsrcrecordid>eNo9kEtLw0AUhYMotVZ_gpCFSwPzyCSZpcRHC5WCKLgLN5MbMzqZhJnUtvjnTW1xdTnfORwu5ySY0izlEeP8_TSYEsJklGZxfB5ceP9JCKGJ5JNgwmLJkjibBj_PXbU2MOjOhmCrcGEHtF7XWh1YV4cQ5jtlur7pfN9Aqyu8Dee4hRaHZmdaNCOzI7vvtp1bl1ppe_vXlWvf76ttuPoGp8GGOViFLnzBD92ivQzOajAer453Frw9Przm82i5elrkd8uoZxmhEZZUyIRQnjKpBGM1yhQVUSAkq5BXJRMVAvBS1YoTngAnAlUMIq7LWJWSz4LrQ2-_Llusit7pFtyuOI4w-jdHH7wCU7vxS-3_Y4mQNM34GIsPsU1nBnT-y6w36IoGwQxNMW5LEiZIRGUmCR9VtJ-b8l9PDXiS</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Modulation and Intensification of a Cyclophosphamide, Hexamethylmelamine, Doxorubicin, and Cisplatin Ovarian Cancer Regimen</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>BRUCKNER, HOWARD W ; COHEN, CARMEL J ; FEUER, ERIC ; HOLLAND, JAMES F</creator><creatorcontrib>BRUCKNER, HOWARD W ; COHEN, CARMEL J ; FEUER, ERIC ; HOLLAND, JAMES F</creatorcontrib><description>For 61 patients with stage III-IV carcinoma of the ovary, chemotherapy consisted first of cisplatin 50 mg/m on day 1, cyclophosphamide 500 mg/m on day 3, doxorubicin 50 mg/m on day 3, and hexamethylmelamine 100 mg/m on days 4-15 every 4 weeks. The dosages of doxorubicin and hexamethylmelamine were increased by 60 and 100%, respectively, until the nadir white blood cell counts fell to 1.0 x 10/L. This regimen was less neurotoxic and nephrotoxic than other intensive treatments and produced better therapeutic effects than did the immediate preceding Mount Sinai regimens1) The overall median survival was 43 months and progression-free survival was 25 months; 2) the greatest benefit occurred among patients under 50 years of age; 3) regression of large tumors increased in frequency, with 33% of tumors 2-6 cm and 16% of tumors larger than 6 cm converted to either pathologically proved remission or microscopic</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>PMID: 2492648</identifier><identifier>CODEN: OBGNAS</identifier><language>eng</language><publisher>New York, NY: The American College of Obstetricians and Gynecologists</publisher><subject>Altretamine - administration & dosage ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Biological and medical sciences ; Chemotherapy ; Cisplatin - administration & dosage ; Cyclophosphamide - administration & dosage ; Doxorubicin - administration & dosage ; Female ; Humans ; Medical sciences ; Middle Aged ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Pharmacology. Drug treatments</subject><ispartof>Obstetrics and gynecology (New York. 1953), 1989-03, Vol.73 (3), p.349-356</ispartof><rights>1989 The American College of Obstetricians and Gynecologists</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6591783$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2492648$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BRUCKNER, HOWARD W</creatorcontrib><creatorcontrib>COHEN, CARMEL J</creatorcontrib><creatorcontrib>FEUER, ERIC</creatorcontrib><creatorcontrib>HOLLAND, JAMES F</creatorcontrib><title>Modulation and Intensification of a Cyclophosphamide, Hexamethylmelamine, Doxorubicin, and Cisplatin Ovarian Cancer Regimen</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>For 61 patients with stage III-IV carcinoma of the ovary, chemotherapy consisted first of cisplatin 50 mg/m on day 1, cyclophosphamide 500 mg/m on day 3, doxorubicin 50 mg/m on day 3, and hexamethylmelamine 100 mg/m on days 4-15 every 4 weeks. The dosages of doxorubicin and hexamethylmelamine were increased by 60 and 100%, respectively, until the nadir white blood cell counts fell to 1.0 x 10/L. This regimen was less neurotoxic and nephrotoxic than other intensive treatments and produced better therapeutic effects than did the immediate preceding Mount Sinai regimens1) The overall median survival was 43 months and progression-free survival was 25 months; 2) the greatest benefit occurred among patients under 50 years of age; 3) regression of large tumors increased in frequency, with 33% of tumors 2-6 cm and 16% of tumors larger than 6 cm converted to either pathologically proved remission or microscopic</description><subject>Altretamine - administration & dosage</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLw0AUhYMotVZ_gpCFSwPzyCSZpcRHC5WCKLgLN5MbMzqZhJnUtvjnTW1xdTnfORwu5ySY0izlEeP8_TSYEsJklGZxfB5ceP9JCKGJ5JNgwmLJkjibBj_PXbU2MOjOhmCrcGEHtF7XWh1YV4cQ5jtlur7pfN9Aqyu8Dee4hRaHZmdaNCOzI7vvtp1bl1ppe_vXlWvf76ttuPoGp8GGOViFLnzBD92ivQzOajAer453Frw9Przm82i5elrkd8uoZxmhEZZUyIRQnjKpBGM1yhQVUSAkq5BXJRMVAvBS1YoTngAnAlUMIq7LWJWSz4LrQ2-_Llusit7pFtyuOI4w-jdHH7wCU7vxS-3_Y4mQNM34GIsPsU1nBnT-y6w36IoGwQxNMW5LEiZIRGUmCR9VtJ-b8l9PDXiS</recordid><startdate>198903</startdate><enddate>198903</enddate><creator>BRUCKNER, HOWARD W</creator><creator>COHEN, CARMEL J</creator><creator>FEUER, ERIC</creator><creator>HOLLAND, JAMES F</creator><general>The American College of Obstetricians and Gynecologists</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198903</creationdate><title>Modulation and Intensification of a Cyclophosphamide, Hexamethylmelamine, Doxorubicin, and Cisplatin Ovarian Cancer Regimen</title><author>BRUCKNER, HOWARD W ; COHEN, CARMEL J ; FEUER, ERIC ; HOLLAND, JAMES F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2801-eb1596013729c522fe97ec0ca592de3db25deaa3bcfc3036a305ec4a54fb4cb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Altretamine - administration & dosage</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BRUCKNER, HOWARD W</creatorcontrib><creatorcontrib>COHEN, CARMEL J</creatorcontrib><creatorcontrib>FEUER, ERIC</creatorcontrib><creatorcontrib>HOLLAND, JAMES F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BRUCKNER, HOWARD W</au><au>COHEN, CARMEL J</au><au>FEUER, ERIC</au><au>HOLLAND, JAMES F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modulation and Intensification of a Cyclophosphamide, Hexamethylmelamine, Doxorubicin, and Cisplatin Ovarian Cancer Regimen</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>1989-03</date><risdate>1989</risdate><volume>73</volume><issue>3</issue><spage>349</spage><epage>356</epage><pages>349-356</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><coden>OBGNAS</coden><abstract>For 61 patients with stage III-IV carcinoma of the ovary, chemotherapy consisted first of cisplatin 50 mg/m on day 1, cyclophosphamide 500 mg/m on day 3, doxorubicin 50 mg/m on day 3, and hexamethylmelamine 100 mg/m on days 4-15 every 4 weeks. The dosages of doxorubicin and hexamethylmelamine were increased by 60 and 100%, respectively, until the nadir white blood cell counts fell to 1.0 x 10/L. This regimen was less neurotoxic and nephrotoxic than other intensive treatments and produced better therapeutic effects than did the immediate preceding Mount Sinai regimens1) The overall median survival was 43 months and progression-free survival was 25 months; 2) the greatest benefit occurred among patients under 50 years of age; 3) regression of large tumors increased in frequency, with 33% of tumors 2-6 cm and 16% of tumors larger than 6 cm converted to either pathologically proved remission or microscopic</abstract><cop>New York, NY</cop><pub>The American College of Obstetricians and Gynecologists</pub><pmid>2492648</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0029-7844 |
| ispartof | Obstetrics and gynecology (New York. 1953), 1989-03, Vol.73 (3), p.349-356 |
| issn | 0029-7844 1873-233X |
| language | eng |
| recordid | cdi_pubmed_primary_2492648 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Altretamine - administration & dosage Antineoplastic agents Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Chemotherapy Cisplatin - administration & dosage Cyclophosphamide - administration & dosage Doxorubicin - administration & dosage Female Humans Medical sciences Middle Aged Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Pharmacology. Drug treatments |
| title | Modulation and Intensification of a Cyclophosphamide, Hexamethylmelamine, Doxorubicin, and Cisplatin Ovarian Cancer Regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A55%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modulation%20and%20Intensification%20of%20a%20Cyclophosphamide,%20Hexamethylmelamine,%20Doxorubicin,%20and%20Cisplatin%20Ovarian%20Cancer%20Regimen&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=BRUCKNER,%20HOWARD%20W&rft.date=1989-03&rft.volume=73&rft.issue=3&rft.spage=349&rft.epage=356&rft.pages=349-356&rft.issn=0029-7844&rft.eissn=1873-233X&rft.coden=OBGNAS&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E2492648%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2492648&rfr_iscdi=true |